Nu Skin’s Aging Platform Gets a $245M Hiccup

The stock has already spoken

Nu Skin’s shares have lost 37% in the last 90 days and sit 96% below their 2013 peak. The second-quarter report didn’t help: revenue fell 12% year-over-year to $321 million, and the company took a $78.9 million non-cash goodwill impairment plus a $167.5 million valuation allowance on U.S. deferred tax assets. The reported loss per share was $5.14. Revenue is now down 49% from its 2021Q2 peak, and the trend is still heading down.

What’s interesting underneath the noise is that Nu Skin is using this quarter to reframe its identity. Management repeatedly ties the future to aging response modulator science, a new research direction that layers epigenetics onto the existing ageLOC platform. Ryan Napierski: “We are expanding our understanding of how nutritional and lifestyle impact biological aging.” That science will power a new wave of innovation, but it won’t help the current numbers.

Prysm iO shifts from placement to consultation

The big product hope, Prysm iO, is now positioned as a wellness engagement tool rather than a home placement device. Napierski: “Many of our sales leaders are primarily using Prysm iO as a wellness consultation tool to invite consumers into their own personal wellness journey.” That learning—from 39,000 devices and 2.5 million scans—is steering the commercial strategy and will be the centerpiece at the Japan live event in September. The problem for the next two quarters is that the pivot hasn’t yet generated the growth needed to offset the slowdown.

The company still guided to 50,000–60,000 devices placed by year end, but the quarter’s cash flow turned negative. Free cash flow excluding SBC came in at –$21 million, a sharp swing from the +$3 million in Q1, and the balance sheet now has net debt of $23 million.

India delays and the East-West shakeup

India was supposed to be the next growth engine, but management pushed the full launch from late 2026 into the first half of 2027. “We’ve decided to move our full market launch into the first half of 2027 to ensure business model, operational and field readiness,” said Napierski. This is a realistic admission that the emerging markets playbook needs another round of tuning. On the cost side, the new East-West operating model is meant to cut G&A and generate $5–$10 million in transition costs this half, but the goodwill impairment suggests the Rhyz manufacturing unit isn’t performing as hoped.

Chelsea Lantz was blunt: “We performed an interim goodwill impairment assessment, resulting in a $78.9 million non-cash goodwill impairment charge related to our Rhyz manufacturing reporting unit.” That, plus the $167.5 million DTA valuation allowance, wiped out reported earnings. Adjusted EPS of $0.20 was in line with guidance, but adjusted operating margin fell to 6.1% from 8% a year ago. The core Nu Skin gross margin actually improved 20bp to 77.7%, but that’s not enough to offset the decline in the Rhyz business.

Priorities and the long road

The call was heavy on leadership development revisions and a new “leader elite” roadmap, but the prior-quarter Q&A already showed these themes. In May, Napierski said “the groups that tend to do that tend to convert best are those who are utilizing it as well as a wellness consultative or wellness assessment tool” — the exact same framing as today’s call. That consistency suggests management is still in the early stages of a multi-quarter transition, not a sudden about-face.

What’s genuinely new this quarter is the scale of the accounting hits and the explicit admission that growth will take longer than planned. The guidance for full-year adjusted EPS of $0.70–$0.90 is well below the earlier $1.20 range. The market is pricing in more downside: the stock trades at 0.2x revenue. Gross margin remains structurally lower than its 2017 high, and the company is betting that the aging response modulator science, combined with the AI-enhanced Prysm app and a leaner East-West structure, can eventually reverse the trend. That’s a thesis the market will need more proof to believe — and the proof is at least a year away.